Kymera Therapeutics (KYMR) Non-Current Assets (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Non-Current Assets data on file, last reported at $991.6 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $991.6 million, up 137.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.8 billion (up 71.91% YoY), and the FY2025 annual result was $871.6 million, up 86.33% from the prior year.
• Non-Current Assets rose to $991.6 million in Q1 2026 per KYMR's latest filing, from $871.6 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $991.6 million in Q1 2026 and troughed at $120.7 million in Q2 2022.
• A 5-year average of $361.7 million and a median of $300.6 million in 2024 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2023 and 2024: Non-Current Assets slipped 7.23% in 2023, then surged 174.44% in 2024.
• A 5-year view of Non-Current Assets shows it stood at $183.7 million in 2022, then fell by 7.23% to $170.4 million in 2023, then surged by 174.44% to $467.8 million in 2024, then jumped by 86.33% to $871.6 million in 2025, then climbed by 13.77% to $991.6 million in 2026.
• Business Quant data shows KYMR's Non-Current Assets at $991.6 million in Q1 2026, $871.6 million in Q4 2025, and $573.7 million in Q3 2025.